ocular surface change after switching from others prostaglandins to tafluprost and preservative free tafluprost in glaucoma
Phase 4
Recruiting
- Conditions
- healthy patient
- Registration Number
- TCTR20170420001
- Lead Sponsor
- Santen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
open angle glaucoma both eyes
C:D ratio < 0.8, VA >6/60
on anti glaucoma drug(prostaglandins group) > 6 months
diagnosis of ocular surface disease both eyes
no other drug used
no history of eye trauma
Exclusion Criteria
history of uveitis or eyelid disease
systemic or topical steroid use in 6 months
contact lens used
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ocular surface change 6 months prospective cohort study
- Secondary Outcome Measures
Name Time Method intraocular pressure control 6 months tension applanation